{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:57:48Z","timestamp":1783133868577,"version":"3.54.6"},"reference-count":36,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2025,4,13]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Overexpression of Preferentially Expressed Melanoma Antigen (PRAME) is associated with melanoma progression. In the case of uveal melanoma (UM), PRAME expression was identified as conferring a metastatic risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study aimed to review the available evidence regarding the prognostic value of PRAME expression in UM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We included cohort studies and randomised clinical trials. The methodological quality of the studies was assessed by the Methodological Index for Non-Randomised Studies (MINORS). The meta-analysis was performed using Review Manager V.5.4. Heterogeneity was checked with the I2 test. If there was no heterogeneity, a fixed-effects model was adopted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nine studies were included. The PRAME+ group showed significant differences in the development of metastases OR (M-H, Fixed, 95%\u2009CI): 3.46 (2.84, 4.22). The PRAME+ group had a significantly shorter time to metastasis MD (IV, Random, 95%\u2009CI): \u221228.31 (\u221255.41, \u20131.22) and a significantly lower percentage metastasis-free survival at 5-year follow-up MD (IV, Fixed, 95%\u2009CI): \u221221.67 (\u221225.74,\u201317.61). PRAME expression was an independent marker for the development of metastatic disease at any follow-up HR (IV, Fixed, 95%\u2009CI): 2.00 (1.60, 2.49). In addition, PRAME+tumours were significantly larger than PRAME\u2212tumours MD (IV, Random, 95%\u2009CI): 0.22 (0.01, 0.42).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PRAME is a good prognostic marker in UM. We believe that further studies are needed to determine the most cost-effective method for reporting PRAME overexpression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jcp-2024-210032","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:20:16Z","timestamp":1745846416000},"page":"519-526","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic value of PRAME expression in uveal melanoma: a meta-analysis"],"prefix":"10.1136","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-6419","authenticated-orcid":false,"given":"Manuel","family":"Perez-Perez","sequence":"first","affiliation":[{"name":"Anatom\u00eda Patol\u00f3gica, Hospital Universitario Quir\u00f3nsalud Sevilla, Seville, Spain"},{"name":"Centro de Anatom\u00eda Patol\u00f3gica y Citopatolog\u00eda Doctor Galera, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garc\u00eda de Sola-Llamas","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Virgen Macarena University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Mariscal","sequence":"additional","affiliation":[{"name":"Facultad de Medicina y Ciencias de la Salud, Universidad Catolica de Valencia San Vicente Martir, Valencia, Valencian Community, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mac\u00edas-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Normal and Pathological Histology and Cytology, University of Seville, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2025092506082133000_78.8.519.1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004153"},{"key":"2025092506082133000_78.8.519.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100081","article-title":"Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas","volume":"36","author":"Han","year":"2023","journal-title":"Mod Pathol"},{"key":"2025092506082133000_78.8.519.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.045"},{"key":"2025092506082133000_78.8.519.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194472"},{"key":"2025092506082133000_78.8.519.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111434","article-title":"A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets","volume":"124","author":"Aljabali","year":"2024","journal-title":"Cell Signal"},{"key":"2025092506082133000_78.8.519.6","doi-asserted-by":"publisher","DOI":"10.1159\/000367715"},{"key":"2025092506082133000_78.8.519.7","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S89591"},{"key":"2025092506082133000_78.8.519.8","doi-asserted-by":"publisher","DOI":"10.1186\/s42047-024-00144-6"},{"key":"2025092506082133000_78.8.519.9","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001242"},{"key":"2025092506082133000_78.8.519.10","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000002863"},{"key":"2025092506082133000_78.8.519.11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13577-022-00808-z","article-title":"Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients","volume":"36","author":"Kumar","year":"2023","journal-title":"Hum Cell"},{"key":"2025092506082133000_78.8.519.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2071"},{"key":"2025092506082133000_78.8.519.13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10962"},{"key":"2025092506082133000_78.8.519.14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050694","article-title":"New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma","volume":"11","author":"Violanti","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025092506082133000_78.8.519.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154543","article-title":"Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases","volume":"247","author":"Broggi","year":"2023","journal-title":"Pathol Res Pract"},{"key":"2025092506082133000_78.8.519.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025092506082133000_78.8.519.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"2025092506082133000_78.8.519.18","doi-asserted-by":"crossref","unstructured":"Higgins J , et al , ed. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2025092506082133000_78.8.519.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.08.001"},{"key":"2025092506082133000_78.8.519.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04335-w"},{"key":"2025092506082133000_78.8.519.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00447"},{"key":"2025092506082133000_78.8.519.22","doi-asserted-by":"crossref","DOI":"10.12775\/QS.2024.23.55123","article-title":"What Sets Uveal Melanoma Apart, and How Can We Address It? A Comprehensive Review of Pathophysiology, Diagnosis and Treatment","volume":"23","author":"Lissak","year":"2024","journal-title":"Qual Sport"},{"key":"2025092506082133000_78.8.519.23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132395","article-title":"Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes","volume":"16","author":"Shannon","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025092506082133000_78.8.519.24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1084\/jem.20232094","article-title":"Divergent local and systemic antitumor response in primary uveal melanomas","volume":"221","author":"Lucibello","year":"2024","journal-title":"J Exp Med"},{"key":"2025092506082133000_78.8.519.25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40359-020-0371-3","article-title":"Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study","volume":"8","author":"Lieb","year":"2020","journal-title":"BMC Psychol"},{"key":"2025092506082133000_78.8.519.26","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001944"},{"key":"2025092506082133000_78.8.519.27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042052"},{"key":"2025092506082133000_78.8.519.28","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14783"},{"key":"2025092506082133000_78.8.519.29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cells13201740","article-title":"The Utilization of PRAME in the Diagnosis, Prognosis, and Treatment of Melanoma","volume":"13","author":"Blount","year":"2024","journal-title":"Cells"},{"key":"2025092506082133000_78.8.519.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers11070984","article-title":"Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025092506082133000_78.8.519.31","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000366"},{"key":"2025092506082133000_78.8.519.32","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2022-0003"},{"key":"2025092506082133000_78.8.519.33","doi-asserted-by":"crossref","unstructured":"Schefler AC , Kim RS . Recent advancements in the management of retinoblastoma and uveal melanoma. F1000Res 2018;7. doi:10.12688\/f1000research.11941.1","DOI":"10.12688\/f1000research.11941.1"},{"key":"2025092506082133000_78.8.519.34","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.43"},{"key":"2025092506082133000_78.8.519.35","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000645"},{"key":"2025092506082133000_78.8.519.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2021.01.001"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2024-210032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:08:30Z","timestamp":1758805710000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2024-210032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jcp-2024-210032"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2024-210032","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}